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In the past decade, the advent of targeted therapy led to a silent revolution
in the war against lung cancer and a significant evolution on the concept
of Phase I clinical trials design. Thanks to the specificity of their target,
the new drugs have radically changed NSCLC treatment, leading to the devel-
opment of personalized strategies. The accelerated approval of the first
ALK-inhibitor, Crizotinib and more recently Ceritinib, without a Phase III
randomized, clinical trial, has been an amazing success story in lung cancer
research, marking the beginning of a new decade of targeted drugs develop-
ment, characterized by modern, biomarker-driven, early clinical trial design
and shorter times for clinical approval. Is Ceritinib a new panacea for the
treatment of ALK-rearranged NSCLC? We aimed to discuss the reasons of
such success, including the new emerging questions, regarding mechanisms
of acquired resistance, and the best treatment algorithm for ALK-rearranged
NSCLC patients.
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The discovery of the EML4-ALK fusion gene, reported in about 3 -- 7% of overall
NSCLC patients [1,2], and the subsequent clinical development of the first ALK-
inhibitor, Crizotinib, has been an amazing success story in lung cancer clinical
and translational research. Its accelerated approval by FDA in October 2011, with-
out a Phase III, randomized, clinical trial, was absolutely uncommon, but it was the
result of the impressive responses (~ 60%), and median progression-free survival
(PFS: 8 -- 10 months), observed in the early Phase I/II clinical trials [3], recently
confirmed by the Phase III, randomized trials, both in second [4,5] and in first-line
settings (biblio). The early approval of Crizotinib has benefited many NSCLC
patients, whose tumors harbor this novel EML4/ALK translocation, marking the
beginning of a new decade of targeted drugs development, characterized by new eth-
ical and scientific considerations. Unfortunately, despite of a dramatic initial activity
of Crizotinib in this, molecularly selected, NSCLC population, acquired resistance
inevitably occurs during the first year of treatment, leading to a clinical progression
of the disease, commonly involving the CNS. Data suggest that additional genetic
alterations in the target, such as secondary mutations or amplification of the ALK
fusion gene, seems to be responsible of the so-called ‘ALK- dependent’ acquired
resistance to Crizotinib in about one-third of the patients [6,7]. The activation
of other oncogenic drivers, such as, K-RAS mutations, KIT amplification and
increased EGFR autophosphorylation and mutations, may cause resistance in
another 30% of them, through reactivation of downstream signaling pathways via
bypass tracts [6,7]. Thus, new drugs capable to overcome mechanisms of acquired
resistance to Crizotinib are urgently needed. Second-generation ALK-inhibitors,
including LDK378, CH5424802, AP26113 and others molecules, are currently
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under investigation in early Phase I/II clinical studies [8]. One
of these compound, LDK378 (Ceritinib), has shown a great
activity in ALK-rearranged, NSCLC patients. In the recent,
Phase I trial by Shaw et al., including a total of 163 patients
with metastatic, ALK-positive, NSCLC who had progressed
on or were intolerant to Crizotinib, Ceritinib induced a
60% response rate, with a median PFS of 7.0 months (95%
CI, 5.6 -- 9.5) [9]. The benefit was similar in both patients
who had received prior Crizotinib treatment and in those
who had not. In addition, responses were seen in untreated
CNS lesions, in patients treated with Crizotinib. The most
common terminology criteria for adverse events grade
3 -- 4 adverse reactions (‡ 5%) were diarrhea, fatigue, hyper-
glycemia, hypophosphatemia, increased transaminases and
lipase levels and anemia. Therefore, a new, more potent
ALK-inhibitor is emerging for ALK-rearranged NSCLC
patients, who could benefit from a second chance of treat-
ment, after progression to Crizotinib occurs. What are the
reasons of such success? First, modifications in the chemical
structure of the compound, promotes a more favorable inter-
action of Ceritinib with the mutant lipophilic residues, at the
gatekeeper position of the kinase domain. The new chemical
architecture could explain the activity of this drug against
both the gatekeeper L1196M, and the non-gatekeeper
G1296A mutations, which are the two most common second-
ary mutations identified in Crizotinib resistant tumors [10].
Second, as reported in the clinical trial, Ceritinib seems to
be effective also in those ‘ALK-indipendent’ resistant patients,
who develops resistance to Crizotinib without ALK mutation
or amplification [9]. These findings suggest that the activity of
Ceritinib in patients whose tumors had progressed during
Crizotinib treatment may be independent of the underlying
mechanism of acquired resistance. In this subset of patients,
tumor cells probably preserve their sensitivity to ALK inhibi-
tion, but, because of a sub-therapeutic inhibition of the target,
during Crizotinib treatment, may survive, through re-
activation of bypass tracks, such as EGFR [10]. Thanks to its
higher potency, Ceritinib completely inhibits the target, stop-
ping the activity of by-pass track, and restoring full tumor
cells sensitivity to ALK-inhibition. Third, the Phase I study
of Ceritinib represent an excellent example of modern, bio-
marker driven, early clinical trial design. Such trial included
a proven oncogenic driver as biomarker, a really effective
drug in modulating the target, and a large, molecular selected,
patients cohort. This made the results of the study even more
reliable and attractive, leading to the accelerated approval by
the FDA on 29 April 2014, for the treatment of patients
with ALK-rearranged NSCLC, with disease progression on,
or who are intolerant to Crizotinib. Furthermore, two
Phase III, ongoing, randomized trials are currently investigat-
ing the role of Ceritinib both in Crizotinib treated
(NCT01828112), and untreated (NCT01828099), NSCLC
patients. Despite several strengths in favor of Ceritinib,
some questions remain open. The evidence of equal efficacy
of Ceritinib treatment, reported in both Crizotinib resistant
and naive patients cohorts, led to a new debate regarding
the best use of this new compound in the treatment of
ALK-rearranged NSCLC patients. Even if most of the
patients included in the trial had previously received Crizoti-
nib, the similar efficacy and tolerability profile of the two
drugs, the higher median PFS achieved in the Crizotinib-
naive cohort, and the early activity on CNS disease, are find-
ings which would support the use of Ceritinib as front-line
treatment. A direct comparison trial between these two com-
pounds is needed, in order to draw up the best treatment algo-
rithm for the ALK-rearranged NSCLC patients. Common to
other tyrosine kinase inhibitors already in use, including its
precursor Crizotinib, after a variable period of response to
Ceritinib, tumors inevitably develop resistance. This has
been clearly shown in the study by Friboulet et al., which
revealed the development of mutations at either G1202 or
F1174, in 5 of 11 biopsed, Ceritinib-resistant tumors [10]. In
addition, the authors reported an inferior activity of Ceritinib
against less common ALK-resistant mutations, such as
C1156Y, 1151T-ins and L1152P, which would confer resis-
tance to both Crizotinib and Ceritinib, in cell-lines
models [10]. Future studies will identify the exact mechanism
behind such resistant mutations, allowing us to understand
whether Ceritinib and new ALK-Inhibitors will be the new
panacea for ALK-rearranged NSCLC.
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